

INTRABIOTICS PHARMACEUTICALS INC /DE

Form 8-K

October 09, 2003

Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 8-K

**Current Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): October 6, 2003

IntraBiotics Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

0-29993

(Commission File No.)

94-3200380

(IRS Employer Identification No.)

2483 East Bayshore Road, Suite 100

Palo Alto, California 94303

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(650) 526-6800**

TABLE OF CONTENTS

Item 5. Other Events and Required Regulation FD Disclosure

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits

SIGNATURE

INDEX TO EXHIBITS

EXHIBIT 10.30

EXHIBIT 10.31

EXHIBIT 99.1

EXHIBIT 99.2

Table of Contents

Item 5. Other Events and Required Regulation FD Disclosure

On October 6, 2003, IntraBiotics Pharmaceuticals, Inc. (the Company) issued a press release entitled, IntraBiotics Raises \$19.2 Million in Private Placement. This press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference. The form of the Common Stock and Warrant Purchase Agreement entered into in the transaction is attached hereto as Exhibit 10.30. The form of the warrant to be issued in the transaction is attached hereto as Exhibit 10.31.

On October 7, 2003, the Company issued a press release entitled, IntraBiotics Enrolls First Patients in Pivotal Trial of Iseganan For Prevention of Ventilator-Associated Pneumonia. This press release is attached as Exhibit 99.2 to this report and is incorporated herein by reference.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits

(c) Exhibits.

10.30	Common Stock and Warrant Purchase Agreement, dated October 6, 2003 (the Purchase Agreement) by and among the Company and each Investor as defined therein.
10.31	Form of warrant issued by the Company in favor of each Investor, as defined in the Purchase Agreement.
99.1	Press Release, dated October 6, 2003, entitled IntraBiotics Raises \$19.2 Million in Private Placement.
99.2	Press Release, dated October 7, 2003, entitled IntraBiotics Enrolls First Patients in Pivotal Trial of Iseganan For Prevention of Ventilator-Associated Pneumonia.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: October 8, 2003

IntraBiotics Pharmaceuticals, Inc.

By: /s/ Eric H. Bjerkholt

Eric H. Bjerkholt
Sr. Vice President and
Chief Financial Officer

Table of Contents

INDEX TO EXHIBITS

- 10.30 Common Stock and Warrant Purchase Agreement, dated October 6, 2003 (the Purchase Agreement) by and among the Company and each Investor as defined therein.
- 10.31 Form of warrant issued by the Company in favor of each Investor, as defined in the Purchase Agreement.
- 99.1 Press Release, dated October 6, 2003, entitled IntraBiotics Raises \$19.2 Million in Private Placement.
- 99.2 Press Release, dated October 7, 2003, entitled IntraBiotics Enrolls First Patients in Pivotal Trial of Isegran For Prevention of Ventilator-Associated Pneumonia.